We are live on ! Find out more
TC

Trium Capital Portfolio holdings

AUM $163M
1-Year Est. Return 45.8%
This Fund
S&P 500
This Quarter Est. Return
-3.48%
1 Year Est. Return
+45.8%
3 Year Est. Return
+188.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$163M
AUM Growth
+$20.6M
Cap. Flow
+$19M
Cap. Flow %
11.69%
Top 10 Hldgs %
79.52%
Holding
80
New
17
Increased
25
Reduced
11
Closed
27

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$31.2M
2
T icon
AT&T
T
+$26.6M
3
ALMS
Alumis Inc
ALMS
+$4.63M
4
ELME
Elme Communities
ELME
+$4.37M
5
NEE icon
NextEra Energy
NEE
+$1.91M

Top Sells

Rank Stock Value
1
STKL
SunOpta
STKL
+$9.32M
2
HOLX
Hologic
HOLX
+$8.51M
3
OS
OneStream Inc
OS
+$6.55M
4
EWZ icon
iShares MSCI Brazil ETF
EWZ
+$6.15M
5
SPNS
Sapiens International
SPNS
+$5.32M

Sector Composition

Rank Sector Weight
1 Communication Services 36.07%
2 Healthcare 29.44%
3 Industrials 14.19%
4 Technology 6.43%
5 Real Estate 3.8%

No holdings matched the selected filter criteria.

1 2 3 4

Similar funds

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
GF
Gimbal Financial Carmel, Indiana $163M AUM
ACM
Arrington Capital Management Miami, Florida $163M AUM
KFS
Krane Financial Solutions Calabasas, California $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
CFG
Cornerstone Financial Group Omaha, Nebraska $162M AUM 14.64% 1-Year Est. Return

Trium Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Trium Capital held 80 positions worth $163M, up 14% from $142M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Trium Capital deployed $19M of net new capital in Q2 2026, opening 17 new positions and adding to 25 existing holdings. Its largest new stake was Esperion Therapeutics: 11,158,150 shares worth $35.3M.

By sector, the portfolio is most concentrated in Communication Services at 36% of assets, up from 25% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Sapiens International, an estimated $5.32M trimmed.

  • Trium Capital's largest Q2 2026 buy was Esperion Therapeutics: 11,158,150 shares worth $35.3M.
  • Trium Capital added most to AT&T in Q2 2026, an estimated $26.6M increase.
  • Trium Capital's biggest Q2 2026 reduction was Sapiens International, cutting an estimated $5.32M.
  • Trium Capital fully exited SunOpta in Q2 2026, selling an estimated $9.32M.
  • Trium Capital's ten largest holdings make up 80% of its $163M portfolio in Q2 2026.
  • Trium Capital opened 17 new positions and closed 27 in Q2 2026.
  • Trium Capital's portfolio value rose 14% quarter-over-quarter to $163M.

Based on Trium Capital's 13F filing for Q2 2026, filed 16 Jul 2026.